Comparing two treatments for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two types of chemotherapy for people with newly diagnosed acute myeloid leukemia (AML). The goal is to see which treatment better lowers signs of cancer in the blood, using a special test that looks for a chemical mark on DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been newly diagnosed with acute myeloid leukemia (AML).
- You have not taken any other experimental cancer treatment in the past 3 weeks.
- You are willing to use effective birth control if needed (or you cannot become pregnant).
- You are not pregnant (if you could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This trial tests two different intensities of venetoclax (a targeted pill) combined with standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The goal is to find out which dose works better and is safer.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests whether giving chemotherapy drugs on a 2-week schedule versus a 3-week schedule works better for newly diagnosed acute myeloid leukemia (a blood cancer). The goal is to find which schedule helps more patients go into remission (where cancer cells disappear).
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.